Literature DB >> 16990018

An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents.

Christoffer Bundgaard1, Martin Jørgensen, Arne Mørk.   

Abstract

INTRODUCTION: Integrated in vivo models applying intracerebral microdialysis in conjunction with automated serial blood sampling in conscious, freely moving rodents are an attractive approach for pharmacokinetic (PK) and simultaneous pharmacokinetic/pharmacodynamic (PK/PD) investigations of CNS active drugs within the same animal. In this work, the ability to obtain and correlate data in this manner was evaluated for the selective serotonin (5-HT) reuptake inhibitor (SSRI) escitalopram.
METHODS: An instrumented rat model equipped with an intracerebral hippocampal microdialysis probe and indwelling arterial and venous catheters was applied in the studies. Concomitant with brain microdialysis, serial blood sampling was conducted by means of an automated blood sampling device. The feasibility of the rat model for simultaneous PK/PD investigations was examined by monitoring plasma and brain extracellular concentrations of escitalopram along with SSRI-associated pharmacological activity, monitored as changes in brain 5-HT levels and plasma corticosterone levels.
RESULTS: Combining intracerebral microdialysis and automated blood sampling did not cause any detectable physiological changes with respect to basal levels of plasma corticosterone or brain 5-HT levels. Furthermore, the PK of escitalopram in hippocampus following intravenous injection was not influenced by the presence of vascular catheters. Conversion of escitalopram dialysate concentrations into absolute extracellular levels by means of in vivo retrodialysis was verified by the no-net-flux method, which gave similar recovery estimates. The PK of escitalopram could be characterized simultaneously in plasma and the hippocampus of conscious, freely moving rats. Concomitantly, the modulatory and functional effects of escitalopram could be monitored as increases in brain 5-HT and plasma corticosterone levels following drug administration. DISCUSSION: The applicability of intracerebral microdialysis combined with arterial blood sampling was demonstrated for simultaneous PK/PD investigations of escitalopram in individual rats under non-stressful conditions. Together, these temporal relationships provide multiple PK/PD information in individual animals, hence minimizing inter-animal variation using a reduced number of animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990018     DOI: 10.1016/j.vascn.2006.07.001

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  5 in total

1.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

2.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

3.  Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice.

Authors:  M Kreilgaard; D G Smith; L T Brennum; C Sánchez
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

4.  Brain Distribution of Drugs: Pharmacokinetic Considerations.

Authors:  Irena Loryan; Margareta Hammarlund-Udenaes; Stina Syvänen
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development.

Authors:  Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.